BioSpace News Archive

Takeda employees worldwide voted to add Access to Health Fund and Bridges to Development as 2020 partners

Oncopeptides AB announces that the Company hosts a symposium at the EHA 25 Virtual Edition on June 13th, focusing on the “Challenges in Managing Patients with Myeloma”.

IDEAYA Biosciences, Inc. is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics.

Verve Therapeutics, a next-generation cardiovascular company developing therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary heart disease, announced it has raised $63 million in a Series A2 financing from both existing and new investors.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, announced its robust schedule of events for the American Diabetes Association 80th Scientific Sessions: A Virtual Experience, June 12 – 16, 2020.

U.K. medical chart study showed an association between patients treated with terlipressin and an improvement in kidney function in 73 percent of hospitalized adult patients with HRS-1

Lannett Company, Inc. said that representatives from the company spoke with and received guidance from the U.S. Food and Drug Administration on the clinical advancement program of its biosimilar insulin glargine partnered product candidate.

BioXcel Therapeutics, Inc., a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, announced that the first patient has been enrolled in the Phase 1b/2 RELEASE trial of BXCL501, the Company’s proprietary sublingual thin-film formulation of dexmedetomidine, for the treatment of opioid withdrawal symptoms.

According to the new research report by Transparency Market Research, the global pharmaceutical hot melt extrusion market will exhibit a CAGR of 3.90% for the given projection period of 2016 to 2024.

Competition is heating up in the global thin film drug manufacturing market owing to astute players betting big on new products by investing heavily in cutting edge research and development.